<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[61, 80] patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy.<br>[230, 231] patients<br></td>
<td width=33%>
[61, 80] patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy.<br>[172, 173] patients<br>[230, 238] patients with AML or MDS who received chemotherapy<br></td>
<td width=33%>
[14, 31] patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.<br>[41, 80] prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy.<br>[120, 123] patients with MDS<br>[172, 180] patients with neutrophil counts of >0.1 x 10(9)/L<br>[230, 238] patients with AML or MDS who received chemotherapy<br></td>
</tr>
